Human Papillomavirus Infection Clinical Trial
Official title:
Prevalence and Type Distribution of Genital Human Papillomavirus (HPV) in Tanzanian Men
The purpose of this study is to determine the prevalence and type distribution of genital human papillomavirus (HPV) infection in Tanzanian men.
STUDY POPULATION The study will be performed in an urban and a rural setting in Tanzania. In
the urban setting we aim to include men from different employment categories at larger
industries, which potentially have already been identified (Twinga cement, ALAF-Aluminum
Company, Bakhresa Food Industry, Simba plastics Industry, and Mohamed Enterprise Food
Industry), and in addition we will include men from the College/University environment in
Dar es Salaam (Vocational Education Training Dar-es-salaam branch, and Dar-es-salaam
Institute of Transport). From the 2002 Census it has been estimated that the population of
Dar es Salaam was 2,497,940
The recruitment of men for the study in the rural setting will take place in villages in the
Kihaba district and the Bagamoyo district.
Kibaha is one of the 6 districts of the Pwani Region located in Eastern Tanzania. It is the
capital of Pwani region. The district is bordered to the North by the Bagamoyo District, to
the East by Dar-es-Salaam, to the South by the Kisarawe District and to the West by the
Morogoro Region. One of the villages potentially selected for this study is Mlandizi village
located in Kibaha district. According to the 2002 Tanzania National Census, the population
of the Kibaha District was 132,045 Bagamoyo is also one of the 6 districts of the Pwani
Region of Tanzania. It is bordered to the North by the Tanga Region, to the West by the
Morogoro Region, to the East by the Indian Ocean and to the South by the Kibaha District.
The district capitol is at Bagamoyo. According to the 2002 Tanzania National Census, the
population of e.g. the Bagamoyo District was 230,164.
The overall study population in the present investigation will include 2000 men aged 18-60
years. Based on our experience from the recent male study conducted in Denmark and also on
the experience obtained in the female study in Tanzania, we will establish a study team that
will travel to the different study sites and obtain the penile samples, do interviews, and
be responsible for the HIV counseling at the respective study site. The study team will
consist of a male doctor to take the penile swabs, two male study assistants to do the
interviews, and one HIV counselor. We will also employ a Danish researcher who will work
together with the Tanzanian doctor and the rest of the study team in the data collection and
entry of the data. Dr. Crispen Kahesa, who was also involved in our study of HPV infection
in Tanzanian women, and the Danish researcher will collaborate in the day-to-day conduct of
the study with the supervision/assistance of Dr Julius Mwaiselage on a weekly basis and with
Professor Susanne Krüger Kjær. Before initiation of the study, the Danish part of the team
from the Danish Cancer Society will teach the investigating team to take the penile swabs so
that it will be done the same way as it was done in the recent Danish male study.
DATA COLLECTION We have chosen an HPV strategy which matches the strategy we are using in
the female Tanzanian study and previously have used in our Danish male study, namely initial
testing with HC2 followed by genotyping of the samples positive for HC2 high-risk (HR) types
and/ or low-risk (LR) types.
HPV DNA prevalence: HPV samples will be obtained by rubbing a moist cotton swab on glans
penis (including sulcus coronarius and underneath preputium), the penile shaft, scrotum and
perineum following a loosening of the cells with a nail file. This procedure is adapted from
the Merck male clinical studies. We have previously documented that this technique is useful
for obtaining HPV samples among men (Morré et al., 2000; Morré et al., 2002; Kjær et al.
2005), and most recently, we have included more than 2,500 men from Danish military barracks
in a study assessing the presence of HPV DNA and HPV type distribution in Danish men. The
HPV samples from the Tanzanian men will be sent with currier to Prof. Iftners laboratory in
Germany where they will be tested for HPV by means of the Hybrid Capture 2 (HC2) method
(Digene), low-risk and high-risk probes.
HPV type distribution: HPV genotyping will be performed using Papillocheck - a DNA-Chip
analysis for the type-specific identification of 18 high-risk and 6 low-risk types of HPV.
Alternatively if funding allows it, we will use a reverse hybridization line probe assay
test (LiPa test) from Innogenetics (which is more expensive, but is slightly more sensitive
than the Papillocheck test, and another advantage is that we have used this test in our
Danish HPV study of 2,500 men). The testing strategy will be to genotype all HC2 positive
(HR positive and/or LR positive) samples.
Assessment of HIV status: An HIV test will be offered to all men enrolled in the study and
performed taking into account the individual person's wish to be tested and informed about
their HIV status. HIV antibody presence in whole blood samples will be assessed following
the WHO approved HIV serial testing algorithm. Initially, the Bioline HIV-1/2
immunodetection is used, and is subsequently followed by Determine HIV-1/2 test in order to
confirm Bioline potentially positive results.
Assessment of risk factors associated with HPV infection: A structured interview focusing on
socio-economic characteristics, circumcision status, sexual activity, STI history and
knowledge about HPV and the HPV/ cancer relationship, will be conducted.
;
Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05458869 -
Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
|
||
Completed |
NCT01932697 -
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT03265743 -
HPV Vaccination in Women With Cystic Fibrosis
|
N/A | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A | |
Completed |
NCT06199128 -
Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients
|
||
Active, not recruiting |
NCT01824537 -
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
|
Phase 4 | |
Unknown status |
NCT01087164 -
Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers
|
N/A | |
Terminated |
NCT01082861 -
Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination
|
Phase 4 | |
Completed |
NCT01265212 -
Prevalence of Human Papillomavirus in Men Living in the Northern Plains
|
N/A | |
Completed |
NCT00572832 -
Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
|
N/A | |
Completed |
NCT03158220 -
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
|
Phase 3 | |
Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
Completed |
NCT05680454 -
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
|
Phase 1 | |
Completed |
NCT04133610 -
HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs
|
N/A | |
Completed |
NCT00988884 -
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
|
Phase 3 | |
Not yet recruiting |
NCT05981807 -
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
|
||
Recruiting |
NCT03302858 -
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand
|
Phase 2 | |
Completed |
NCT01694875 -
Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System
|
N/A | |
Completed |
NCT01158209 -
An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in Egypt
|
N/A |